IRLAB Therapeutics AB (publ) - Asset Resilience Ratio

Latest as of December 2025: 59.23%

IRLAB Therapeutics AB (publ) (IRLAB-A) has an Asset Resilience Ratio of 59.23% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IRLAB Therapeutics AB (publ) (IRLAB-A) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr81.86 Million
≈ $8.81 Million USD Cash + Short-term Investments

Total Assets

Skr138.21 Million
≈ $14.87 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how IRLAB Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see IRLAB-A asset base.

Liquid Assets Composition Over Time

This chart breaks down IRLAB Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of IRLAB Therapeutics AB (publ) for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr81.86 Million 59.23%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr81.86 Million 59.23%

Asset Resilience Insights

  • Very High Liquidity: IRLAB Therapeutics AB (publ) maintains exceptional liquid asset reserves at 59.23% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

IRLAB Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio

Compare IRLAB Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 62.24%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%
Wecome Pharmaceutical Co Ltd
SHE:300878
Biotechnology 0.67%
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Biotechnology 86.66%
Relmada Therapeutics Inc
NASDAQ:RLMD
Biotechnology 95.25%
MediWound Ltd
F:M8W
Biotechnology 56.04%

Annual Asset Resilience Ratio for IRLAB Therapeutics AB (publ) (2016–2025)

The table below shows the annual Asset Resilience Ratio data for IRLAB Therapeutics AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 59.23% Skr81.86 Million
≈ $8.81 Million
Skr138.21 Million
≈ $14.87 Million
+10.10pp
2024-12-31 49.13% Skr66.92 Million
≈ $7.20 Million
Skr136.21 Million
≈ $14.66 Million
-13.72pp
2023-12-31 62.84% Skr111.31 Million
≈ $11.98 Million
Skr177.12 Million
≈ $19.06 Million
-15.28pp
2022-12-31 78.12% Skr252.78 Million
≈ $27.20 Million
Skr323.56 Million
≈ $34.82 Million
-6.94pp
2021-12-31 85.07% Skr401.90 Million
≈ $43.25 Million
Skr472.45 Million
≈ $50.84 Million
+10.21pp
2020-12-31 74.85% Skr277.01 Million
≈ $29.81 Million
Skr370.07 Million
≈ $39.83 Million
+21.73pp
2019-12-31 53.12% Skr110.53 Million
≈ $11.89 Million
Skr208.07 Million
≈ $22.39 Million
-6.65pp
2018-12-31 59.77% Skr134.44 Million
≈ $14.47 Million
Skr224.94 Million
≈ $24.21 Million
+13.93pp
2017-12-31 45.84% Skr74.71 Million
≈ $8.04 Million
Skr162.97 Million
≈ $17.54 Million
+23.09pp
2016-12-31 22.75% Skr25.74 Million
≈ $2.77 Million
Skr113.11 Million
≈ $12.17 Million
--
pp = percentage points

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology
Market Cap
$15.76 Million
Skr146.47 Million SEK
Market Cap Rank
#25934 Global
#530 in Sweden
Share Price
Skr1.73
Change (1 day)
-0.46%
52-Week Range
Skr1.20 - Skr3.04
All Time High
Skr104.95
About

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more